The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the ...

Following a reportedly bullish assessment from Medicare, Eisai has projected a significant sales increase for Leqembi. Takeda ...

China-made PD-1 inhibitors just can’t get a clean pass through the FDA.  | China-made PD-1 inhibitors continue to struggle at ...

Following a controversy over Covis’ preterm birth drug Makena in the U.S. last year, the European Medicines Agency (EMA) is ...

Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer ...

Right on the heels of a similar move by Johnson & Johnson, GSK is offloading the rest of its stake in the consumer healthcare ...

This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and ...

After Moderna last year suffered a loss in its heated patent fight against Pfizer and BioNTech, the mRNA drugmaker can now ...

The company formerly known as First Wave BioPharma has found itself on dry land with a decidedly non-aquatic new moniker. The ...

AbbVie’s newest psoriasis awareness-raising campaign is taking the skin condition out of the spotlight. | AbbVie’s newest ...

After recently placing a spotlight on Novo Nordisk’s "outrageous" U.S. | A new Senate HELP Committee report says GLP-1 drugs ...

When Bayer unveiled a restructuring in January, the company didn’t provide specifics on the number of planned job cuts. | ...